Mandate

VINGE ADVISES GRÄNGES IN CONNECTION WITH THE LISTING ON NASDAQ STOCKHOLM

October 10, 2014

Vinge advises Gränges AB (publ) in connection with the company’s listing on Nasdaq Stockholm.

Gränges is a leading global supplier of rolled products for the brazed aluminum heat exchanger industry. The Company develops, produces and markets advanced materials that enhance both production economy during the customer manufacturing process, as well as the performance of the final products, the brazed heat exchangers. Gränges’ vision is to help create smaller, lighter and more designable heat exchangers, to increase economic efficiency and reduce environmental impact. The Swedish language prospectus was published on 29 September 2014 and the first day of trading was 10 October 2014. The offering price has been set at SEK 42.50 per share, corresponding to a market value of Gränges of approximately SEK 3,200 million.

Vinge’s team primarily consisted of Carl Gustaf de Geer, Jesper Schönbeck, Charlotte Levin, Katarina Nilsson, Kristian Ford, Rikard Lindahl, Filip Brosset and Henrik Jonsson.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026